It has been reported that K-ras mutation is predictive of a very poor response to signal inhibitors which inhibit the downstream effector pathways of K-ras, such as the mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K) signaling pathways in colorectal cancer[45–48]. Here, KRAS is linked to colorectal cancer.